公开(公告)号：US06133281A

公开(公告)日：2000-10-17

申请号：US956907

申请日：1997-10-23

申请人： Nestor F. Gonzalez-Cadavid ,  Jacob A. Rajfer

发明人： Nestor F. Gonzalez-Cadavid ,  Jacob A. Rajfer

IPC分类号： A61K31/13 ,  A61K31/135 ,  A61K31/485 ,  A61K31/4748

CPC分类号： A61K31/13 ,  A61K31/135 ,  A61K31/485

摘要： Methods are presented for the treatment of benign prostatic hyperplasia. The methods provide for administration to a person at least one compound identified generically as antagonists of N-methyl-D-aspartate receptors. These compounds are selected from the group consisting of memantidine, amantidine, dextromethorphan and ketamine.

摘要翻译： 提出了治疗良性前列腺增生的方法。 所述方法提供给人一种至少一种化合物的化合物，其通常称为N-甲基-D-天冬氨酸受体的拮抗剂。 这些化合物选自美丹啶，金刚烷胺，右美沙芬和氯胺酮。

公开(公告)号：US5929084A

公开(公告)日：1999-07-27

申请号：US860524

申请日：1997-06-27

申请人： Dayuan Zhu ,  Xican Tang ,  Jinlai Lin ,  Cheng Zhu ,  Jingkang Shen ,  Guansong Wu ,  Shanhao Jiang ,  Takuji Yamaguchi ,  Kazuhiro Tanaka ,  Takeshi Wakamatsu ,  Hiroaki Nishimura

发明人： Dayuan Zhu ,  Xican Tang ,  Jinlai Lin ,  Cheng Zhu ,  Jingkang Shen ,  Guansong Wu ,  Shanhao Jiang ,  Takuji Yamaguchi ,  Kazuhiro Tanaka ,  Takeshi Wakamatsu ,  Hiroaki Nishimura

IPC分类号： A61K31/435 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4748 ,  A61K36/18 ,  A61P21/00 ,  A61P25/28 ,  C07D221/22 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D221/06

CPC分类号： C07D401/06 ,  C07D221/22 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12

摘要： The present invention relates to novel huperzine A derivatives of formula (II), wherein Y is ##STR1## or R" and Y together form .dbd.CH; R is (C.sub.1 -C.sub.5) alkyl, ##STR2## wherein n is 0 or 1, X is H, (C.sub.1 -C.sub.5) alkyl; (C.sub.1 -C.sub.5) alkyloxy; nitro, halogen, carboxy, alkyloxycarbonyl, hydroxymethyl, hydroxy, amino substituted by bis-(C.sub.1 -C.sub.5) alkyl; --(CH.sub.2).sub.m COOZ, wherein m=0-5, Z is H or (C.sub.1 -C.sub.5) alkyl; --CH.dbd.CH--G, wherein G is phenyl, furanyl, carboxy, alkyloxycarbonyl; and dihydro- or tetrahydro-pyridyl substituted by (C.sub.1 -C.sub.5) alkyl at the nitrogen atom; R' is H, (C.sub.1 -C.sub.5) alkyl, pyridoyl, benzoyl substituted by (C.sub.1 -C.sub.5) alkyloxy; R" is H or (C.sub.1 -C.sub.5) alkyl; processes for their use as acetylcholinesterase inhibitor. ##STR3##

摘要翻译： PCT No.PCT / CN95 / 00100 Sec。 371日期：1997年6月27日 102（e）日期1997年6月27日PCT提交1995年12月26日PCT公布。 公开号WO96 / 20176 日期：1996年7月4日本发明涉及式（Ⅱ）的新型石杉碱甲衍生物，其中Y为或R“和Y一起形成= CH; R为（C 1 -C 5）烷基，其中n为0或1，X为H，（C 1 -C 5）烷基; （C1-C5）烷氧基; 硝基，卤素，羧基，烷氧基羰基，羟甲基，羟基，被双 - （C 1 -C 5）烷基取代的氨基; - （CH 2）m COOZ，其中m = 0-5，Z是H或（C 1 -C 5）烷基; -CH = CH-G，其中G是苯基，呋喃基，羧基，烷氧基羰基; 在氮原子被（C 1 -C 5）烷基取代的二氢或四氢吡啶基; R'是H，（C1-C5）烷基，吡啶基，（C1-C5）烷氧基取代的苯甲酰基; R“是H或（C 1 -C 5）烷基; 它们用作乙酰胆碱酯酶抑制剂的方法。

公开(公告)号：US11541021B2

公开(公告)日：2023-01-03

申请号：US17002017

申请日：2020-08-25

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/137 ,  A61K31/485 ,  A61K31/135 ,  A61K9/00 ,  A61K31/4748

摘要： Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

公开(公告)号：US20220362341A1

公开(公告)日：2022-11-17

申请号：US17744590

申请日：2022-05-13

申请人： Therapeutic Solutions International, Inc.

发明人： Thomas E. ICHIM ,  Timothy G. DIXON ,  Kalina O'CONNOR ,  Wais KAIHANI

IPC分类号： A61K38/20 ,  A61P25/24 ,  A61K31/09 ,  A61K33/241 ,  A61K31/164 ,  A61K31/375 ,  A61K31/4748 ,  A61K31/4365 ,  A61K31/352 ,  A61K31/05 ,  A61K31/121 ,  A61K31/047 ,  C12N15/113

摘要： Disclosed are methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration of low dose interleukin-2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as a treatment of major depressive disorder.

公开(公告)号：US20220313677A1

公开(公告)日：2022-10-06

申请号：US17660673

申请日：2022-04-26

申请人： Novartis AG

发明人： Michael BADMAN ,  Jin CHEN ,  Bryan LAFFITTE ,  Sam LINDGREN

IPC分类号： A61K31/46 ,  A61K31/506 ,  A61K31/497 ,  A61K31/4748 ,  A61K47/54 ,  A61P1/16 ,  A61K9/00

摘要： The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.

公开(公告)号：US11433066B2

公开(公告)日：2022-09-06

申请号：US17032882

申请日：2020-09-25

申请人： Orexo AB

发明人： Andreas Fischer

IPC分类号： A61K31/485 ,  A61K9/14 ,  A61K9/20 ,  A61K9/00 ,  A61K31/4748

摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

公开(公告)号：US11406709B2

公开(公告)日：2022-08-09

申请号：US15510965

申请日：2015-09-15

申请人： TRUSTEES OF BOSTON UNIVERSITY

发明人： Nader Rahimi

IPC分类号： A61K38/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07K1/00 ,  C07K14/00 ,  A61K38/16 ,  A61K39/395 ,  C07K14/47 ,  A61K38/17 ,  A61K31/513 ,  A61K31/4748 ,  A61K45/06 ,  A61K31/475 ,  A61K31/122 ,  A61K31/404 ,  A61K31/12 ,  A61K31/13 ,  A61K31/4035 ,  A61K31/428 ,  A61K31/4709 ,  A61K31/519 ,  A61K31/277 ,  A61K31/7115 ,  A61K38/02 ,  C07K16/28

摘要： Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.

公开(公告)号：US20220110832A1

公开(公告)日：2022-04-14

申请号：US17420618

申请日：2020-01-22

申请人： SHANGHAI WD PHARMACEUTICAL CO., LTD

发明人： Liang Chang DONG ,  Yang LEI ,  Gang WU ,  Yan JIAO ,  Jingmin SHI

IPC分类号： A61J7/00 ,  A61K31/4439 ,  A61K31/197 ,  A61K31/47 ,  A61K31/43 ,  A61K31/7048 ,  A61K31/167 ,  A61K31/4748 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/138

摘要： Disclosed is an oral drug delivery device, comprising a tubular member, a drug holding part, a device cap and a turbulence-creating means. The tubular member has openings at both ends and an inner cavity; the opening at one end is a first opening and the opening at the other end is a second opening; the inner cavity communicates the first opening and the second opening. The turbulence-creating means comprises a step structure or a fold structure, and is disposed in the inner cavity and positioned between the second opening and the drug holding part. By using the oral drug delivery device of the present invention, turbulence can be generated during a normal sipping process, thereby providing ample mixing of drug-containing granules or multi-particulates with drinkable liquids. Moreover, the device is telescopic, which reduces the size and is convenient to carry.

公开(公告)号：US11241420B2

公开(公告)日：2022-02-08

申请号：US16046343

申请日：2018-07-26

申请人： Omeros Corporation

发明人： Roberto Ciccocioppo

IPC分类号： A61K31/4439 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/195 ,  A61K31/35 ,  A61K31/4015 ,  A61K31/4178 ,  A61K31/445 ,  A61K31/519 ,  A61K31/70 ,  A61K45/06 ,  A61K31/485 ,  A61K31/4184 ,  A61K31/425 ,  A61K31/135 ,  A61K31/197 ,  A61K31/426 ,  A61K31/4748 ,  A61K31/55

摘要： The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPARγ agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviours, including pathological gambling and pathological overeating.

公开(公告)号：US11135215B2

公开(公告)日：2021-10-05

申请号：US17142723

申请日：2021-01-06

申请人： Camurus AB

发明人： Fredrik Tiberg ,  Ian Harwigsson ,  Markus Johnsson

IPC分类号： A61K31/4748 ,  A61K31/485 ,  A61K47/10 ,  A61K47/24 ,  A61K47/34 ,  A61K9/00 ,  A61K47/14

摘要： A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.